Handa Pharma, Inc.

Company overview. Handa Pharma, Inc. is a U.S. subsidiary of Handa Pharmaceuticals, Inc. (漢達生技醫藥), a Taiwan-headquartered specialty pharmaceutical company listed on the Taipei Exchange (TPEX: 6620). Handa Pharma is incorporated in Delaware with its principal place of business in San Jose, California, where it shares an office with sibling U.S. entities. Per court filings, Handa Pharma was created in July 2020; Novartis describes it as the group's business-development, intellectual-property, and regulatory-affairs arm, while Handa has characterized it as a holding company for U.S. subsidiaries. The parent was established in 2014 (its U.S. predecessor dates to 2005) and reported roughly 41 global employees in a late-2025 company presentation; 2024 consolidated revenue was about NT$831 million (~US$26 million), per press coverage.

Products / operations. Handa Pharma's own site describes a Bay Area specialty-pharma operation that develops and commercializes prescription medications through wholly owned subsidiaries, including Handa Pharmaceuticals, LLC (generics), Handa Neuroscience, LLC, and Handa Therapeutics, LLC. The group develops high-barrier controlled-release generics (ANDAs) and 505(b)(2) NDAs for the U.S. market. FDA-approved group products include TASCENSO ODT (fingolimod ODT for multiple sclerosis) and Phyrago (a kinase inhibitor for leukemias), plus marketed Quetiapine XR and Dexlansoprazole DR capsules and oncology/neurology pipeline candidates (HND-027, HND-039, HND-044, HND-045).

Patent-litigation posture. Handa Pharma is an operating-company defendant, not an NPE: it appears in one tracked case as defendant and none as plaintiff. That case, Novartis Pharmaceuticals Corp. v. Handa Neuroscience, LLC et al. (D. Del., filed May 2021), is Hatch-Waxman litigation over TASCENSO ODT 0.5 mg, a 505(b)(2) version of Novartis's GILENYA, asserting U.S. Patent Nos. 9,187,405 and 10,543,179. The venue is Delaware — typical for ANDA/505(b)(2) litigation — not the Eastern District of Texas.

Notable context. The parties settled in October 2022; under the settlement Handa agreed to pay Novartis royalties on U.S. net sales under specified conditions, and the litigation was dismissed. Company filings from mid-2026 additionally report a separate Exelixis patent-infringement suit over oncology candidate HND-039 naming Handa Pharma and Handa Oncology, LLC as defendants — a matter not reflected in the tracked case list.